Company / Operating Cash Flow
Tempest Therapeutics, Inc. Operating Cash Flow History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$50.3M
FY2017
5-year range
-$50.3M / -$18.1M
FY2015-FY2017
Trend
-64.4%
vs FY2016
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$18M to -$50M over the past 2 years.
Based on SEC 10-K filings.
-$50M in FY2017.
Declined from -$18M to -$50M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2017, operating cash flow decreased 64.4% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2017 | -$50.3M | -64.4% |
| FY2016 | -$30.6M | -69.1% |
| FY2015 | -$18.1M | - |
As of FY2017 · SEC 10-K · Updated Jun 28, 2026